Samsung Biologics will develop a rapid vaccine manufacturing process under an agreement with CEPI to prepare for future pandemics, focusing on mammalian cell-based production methods. This partnership aims to minimize activation time and ensure quick deployment of vaccines globally, especially in underserved regions, enhancing global preparedness against emerging health threats.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
8
Comments
Ali NematiWritten by Ali
